GEN Exclusives

More »

GEN News Highlights

More »
Aug 14, 2007

CEL-SCI Secures Manufacturing Facility for Cancer Drug

  • CEL-SCI entered into an agreement with a biomedical real estate group under which it acquires long-term use of a dedicated manufacturing plant near Baltimore for its cancer drug Multikine. The financial value of this transaction to CEL-SCI is about $15 million.

    BioRealty is responsible for its build-out pursuant to CEL-SCI's specifications. Once fully built, the facility will produce Multikine for its Phase III trials for head and neck cancer as well as other oncology indications, following marketing approval for sale. The company reports that this transaction allows it to preserve its cash as well as pursue the development of its cancer drug in the most prudent manner.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?